Jordan Breffle

Target-biology and interactome-derived signatures predict target-level associations with safety-related drug attrition

Clinical drug development suffers from high rates of toxicity-related failure despite the use of compound-centric preclinical safety screening, with approximately one-third of all clinical failures attributable to safety concerns. An ability to prioritize early-stage drug development programs toward those with a lower...